阿立哌唑治疗老年精神分裂症的疗效和安全性探讨

Observations on efficacy and safety of aripiprazole in the treatment of senile schizophrenia

目的探讨阿立哌唑治疗老年精神分裂症的疗效和安全性。方法选择2014年5月至2016年4月本院收治的86例老年精神分裂症患者作为研究对象,随机分为对照组(43例)和观察组(43例)。观察组采用阿立哌唑治疗,对照组采用齐拉西酮治疗,比较两组患者临床疗效、阳性与阴性症状量表(PANSS)评分、临床总体印象量表(CGI)评分及不良反应发生情况。结果观察组治疗总有效率为95.35%,显著高于对照组的81.40%(P<0.05);治疗4周、8周后,观察组PANSS量表总分、CGI评分均显著低于对照组(P<0.05);观察组不良反应发生率(16.28%)略低于对照组(20.93%),但无显著差异(P>0.05)。结论阿立哌唑治疗老年精神分裂症的疗效理想,临床应用安全可靠。

Objective To investigate the efficacy and safety of aripiprazole in the treatment of senile schizophrenia.Methods Eighty-six cases of elderly patients with schizophrenia from May 2014 to April 2016 in our hospital were selected and randomly divided into control group（43 cases） and observation group（43 cases）. The observation group was treated with aripiprazole, while the control group received ziprasidone treatment, the clinical curative effect, positive and negative symptoms scale（PANSS） score, clinical global impression scale（CGI） score and adverse reactions between the two groups were compared. Results The total effective rate in the observation group was 95.35%, which was higher than 81.40% of the control group（P〈0.05）. Four and 8 weeks after the treatment, the PANSS score and CGI score in the observation group were significantly lower than those in the control group（P〈0.05）. The adverse reactions rate of the observation group was16.28%, which was slightly lower than 20.93% of the control group, but there was no significant difference（P〉0.05）.Conclusion The curative effect of aripiprazole in the treatment of senile schizophrenia is good, and the clinical application is safe and reliable.